Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 7, 2007

Correlogic Systems and JEOL Sign R&D Agreement for Clinical Application of Mass Spec

  • Correlogic Systems and JEOL signed a research and development agreement focused on further enhancing the performance of mass spectrometry in a clinical setting. Correlogic and JEOL have collaborated for more than a year under an informal agreement and have made great strides in the continuing validation of various mass spectrometer-based assays, according to the companies.

    “Over the past year, we have had a very close and productive research collaboration with JEOL,” said Peter J. Levine, president and CEO of Correlogic Systems. “This agreement formalizes our link.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »